Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarter Ended March 31, 2019
10 avr. 2019 16h35 HE
|
Vital Therapies, Inc.
SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL) announced that it had filed its quarterly report on Form 10-Q today. The report was filed earlier than usual to...
Vital Therapies, Inc. Announces Stockholder Approval of Business Combination with Immunic AG
04 avr. 2019 16h07 HE
|
Vital Therapies, Inc.
SAN DIEGO, April 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL) announced that its stockholders voted to approve the proposals required to complete the business combination with...
Vital Therapies Reminds Stockholders to Vote For the Proposed Business Combination With Immunic AG
27 mars 2019 06h00 HE
|
Vital Therapies, Inc.
Of the Votes Received to Date, More than 98% are Voting in Favor of the Business CombinationMore Votes are Needed to Reach 50% of the Outstanding Shares Required for the Business Combination to Go...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Vital Therapies Stockholders Vote “FOR” the Proposed Business Transaction With Immunic AG and All the Related Proposals
25 mars 2019 05h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, March 25, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL) announced today that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co., LLC (Glass Lewis) have both...
Vital Therapies Announces 2018 Financial Results
04 mars 2019 16h10 HE
|
Vital Therapies, Inc.
SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute...
Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company
07 janv. 2019 04h00 HE
|
Vital Therapies, Inc.
– Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets – – Lead Program, IMU-838, an...
Vital Therapies Announces Third Quarter 2018 Financial Results
07 nov. 2018 18h20 HE
|
Vital Therapies, Inc.
SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute forms...
Vital Therapies Provides Strategic Update
11 oct. 2018 09h27 HE
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of liver...
Vital Therapies to Present at the 19th International Liver Support Meeting
29 sept. 2018 10h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 29, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of liver...
Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival
12 sept. 2018 05h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...